Standout Papers

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell... 2021 2026 2022 2024230
  1. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer (2021)
    Jie Wang, Shun Lü et al. JAMA Oncology

Citation Impact

1 by Nobel laureates 4 from Science/Nature 79 standout
Sub-graph 1 of 23

Citing Papers

Targeting KRAS in cancer
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
1 intermediate paper

Works of Yanping Hu being referenced

137MO Phase II study of becotarug (JMT101) combined with osimertinib in patients (pts) with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion (ex20ins) mutations (BECOME study)
2024
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
2020
and 2 more

Author Peers

Author Oncology Molecular Biology PRM Last Decade Papers Cites
Yanping Hu 712 734 427 109 1.6k
David J. Frankowski 1 35 9 313
C. Lashley 6 283
Amber R. Hackett 17 138 9 12 369
Gail M. Sloane 4 11 415
Angela McRae 1 4 512

All Works

Loading papers...

Rankless by CCL
2026